Edgington-Mitchell LE. Pathophysiological roles of proteases in gastrointestinal disease.
GASTROINTESTINAL DISEASES like irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and colorectal cancer (CRC) are associated with altered bowel habits and abdominal pain. In IBD, which encompasses Crohn's disease (CD) and ulcerative colitis (UC), damage to the intestinal epithelium leads to impaired barrier function. This leakiness allows microbes to invade into the intestinal mucosa, where they incite an inflammatory response. Infiltrating immune cells, including neutrophils, macrophages, and mast cells, are a rich source of proteases. Although the pathophysiological roles of these enzymes are still incompletely understood, there is a growing body of evidence to suggest that they modulate the inflammatory response and promote tissue damage (see Proteases Implicated in Gastrointestinal Disease). The etiology of IBS is less well defined. Although it is not usually characterized by overt signs of inflammation, an increase in mast cell activity has been reported in IBS patients (1, 4, 18, 51) . Furthermore, some cases of IBS result from a previous intestinal infection; therefore, proteases produced during inflammation could potentially have lasting effects.
The most basic function of proteases is to cleave amide bonds of proteins, and as such they are critical for digestion and maintenance of protein homeostasis. Beyond this, proteases also participate in complex signaling pathways that govern normal physiological processes such as apoptosis, antigen presentation, blood coagulation, and prohormone processing. To prevent aberrant activity, proteases are subject to tight regulation (Fig. 1A) . Most proteases are synthesized as inactive zymogens that become activated through a number of mechanisms, including cleavage by upstream proteases, changes in pH, or dimerization. Once the protease is in the active conformation, substrates can enter the active site and be cleaved. Proteases are also subject to inactivation by endogenous inhibitors; thus the balance of active and inactive proteases is tightly controlled. Given the complex nature of their regulation, it is unsurprising that dysregulated proteolytic activity is associated with many disease states. This review will provide an overview of methods that have been used to study proteases in the gut followed by a summary of the key data that support a role for selected host-derived proteases in IBD, IBS, and CRC. Matrix metalloproteases (MMPs) contribute to the pathogenesis of IBD; however, they are omitted from this discussion because they have been recently reviewed (52) . Furthermore, bacterial proteases are important in gastrointestinal disease, and they have recently been reviewed (62) .
Tools To Study Proteases
Many of the literature reports focused on proteases in IBS and IBD have examined changes in total mRNA and protein levels; however, this does not always reflect the pool of active, functional proteases. Several assays have been developed to aid in determining the active population of proteases in the gut. The most basic of these monitors cleavage of azocasein to reflect levels of total proteolysis (7) . Azocasein is a nonspecific chromogenic substrate that releases azo dye into the media upon cleavage. The absorption of the dye at 440 nm is measured to reflect proteolytic activity. Most proteases can cleave azocasein; however, this method cannot detect enzymes with very strict specificity. Furthermore, this assay is not ideal for determining the exact identity of the casein-cleaving proteases and is only used to approximate total levels of proteolysis. Protease inhibitors can be used to block the activity of certain proteases, and these can provide clues about the nature of the proteases in the sample. Truly specific inhibitors are required to definitively identify the enzymes that produce the colorimetric signal; however, these are not available for all proteases given that many have overlapping substrate specificity.
Substrate-based probes are tools that can detect the activity of more specific proteases within a complex protein sample (Fig. 1B) (10, 58) . These probes usually contain a peptide sequence that is based on the preferred cleavage site for an individual protease or group of proteases. Cleavage of the probe gives rise to a change in spectral properties that can be detected by measuring absorption or fluorescence. A common chromogenic substrate that has been used to measure gut proteases makes use of the p-nitroaniline group, which yields a yellow color upon cleavage that can be detected by measuring absorption at 405 nm. Caution should be taken when using this approach given that proteins found in blood, such as hemoglobin, also absorb in this region of the visible spectrum (34) . Since gastrointestinal diseases can be associated with an increase in intestinal bleeding or fecal blood, hemoglobin can produce background signal that could be easily mistaken for proteolytic release of p-nitroaniline. Fluorogenic substrates, which generate fluorescence upon proteolytic cleavage, are often a better alternative to chromogenic substrates since autofluorescence of proteins is usually quite low. Aminomethylcoumarin is a commonly used dye in substrate probes that yields low fluorescence until released into the media by proteolytic cleavage. A common caveat of substrate probes is their lack of selectivity (10, 58) . Many of these probes are marketed commercially as being specific for one protease over another. In practice, however, many substrate probes can be cleaved by multiple proteases given overlap in their specificity. As with azocasein, it is difficult to definitively identify the proteases that yield signal, and, as result, data in the literature mostly report on groups of proteases with similar specificity (e.g., trypsin-like proteases) rather than specific proteases.
Activity-based probes (ABPs) are another class of tools that can report protease activity ( Fig. 1C) (10, 58) . ABPs contain a reactive electrophile that binds specifically and irreversibly to a protease class of interest (e.g., cysteine proteases). Specificity toward individual proteases can be directed through the introduction of optimized recognition sequences. These are usually peptidic in nature, but recently more efforts have been made to diversify these sequences using nonnatural amino acids and nonpeptidic moieties to develop more specific probes (30, 55, 66) . ABPs can be labeled with fluorophores or tags that can be used for affinity purification (e.g., biotin or azide/alkyne handles for click chemistry). The main advantage of using ABPs over substrate-based probes is their irreversible nature. This are synthesized as inactive zymogens (purple/ dark blue) that become active through a number of mechanisms. Once active, they can also be inhibited by endogenous inhibitors (red) that prevent substrates from accessing the active site. Only the active proteases can hydrolyze protein substrates (light blue) and perform biological functions. B: schematic of a substrate-based probe for proteases. A chromophore or fluorophore (gray) is attached to a short peptide (light blue). This peptide mimics the residues on the prime side of the cleavage site of a specific protease substrate (designated P1-P4). When the protease is cleaved after the P1 residue, a shift in absorption or emission can be detected. (yellow). (OH and SH represent the catalytic hydroxyl and thiol groups of serine and cysteine proteases, respectively.) The protease is then free to cleave additional substrate molecules. It is difficult to obtain substrates with absolute specificity, and most can be cleaved by multiple enzymes. C: schematic of an activity-based probe for proteases. A reactive group called a warhead (green) is attached to a peptide, both of which are flanked by a fluorophore (gray) and a quenching group (red). When the protease attacks the warhead, the quenching group is released, and fluorescence can be detected. The warhead remains covalently bound to the protease, making it inactive and unable to bind to additional probe molecules. Because the modification is irreversible, the identity of the labeled proteases can be subsequently confirmed by immunoprecipitation with proteasespecific antibodies.
allows for purification of probe-labeled proteases and subsequent identification by mass spectrometry (61) . Alternatively, ABP targets can be confirmed by immunoprecipitation with antibodies (9) . Thus, even when ABPs are not completely specific, the identity of the bound proteases can usually be determined with certainty, making this the most preferred approach.
Most of the data on proteases in gastrointestinal diseases have been generated by using substrate probes on dissociated tissues in vitro. Sample preparation is likely to disrupt the spatial compartmentalization of proteases and their inhibitors and alter the local pH. As a result, the measured protease activity likely differs from their actual levels in vivo. Where possible, it is preferable to study proteases in their natural environment. Activity-based probes enable this in animal models of disease. Fluorescent probes can be injected intravenously and protease activity can be detected in situ by whole animal imaging or ex vivo imaging of tissues. Because ABPs covalently bind the proteases, they are retained in tissues at the sites of activity. Tissues can therefore be analyzed by fluorescence microscopy or flow cytometry to determine the cell-specific distribution of active proteases. Perhaps most importantly, the probe-labeled proteases can be analyzed biochemically by using fluorescent SDS-PAGE followed by Western blotting with protease-specific antibodies. Active protease levels can then be quantified as a percentage of total protease expression and compared in normal and diseased tissues. Since ABPs have not yet been approved for patient use, studies on human tissue are limited to ex vivo analyses on intestinal biopsies, luminal fluids, or fecal samples. Assessing protease activity after minimal manipulation is most likely to yield results that reflect their levels in situ.
Proteases Implicated in Gastrointestinal Disease
Mast cell tryptase. Several studies have reported an increase in total proteolytic activity in patients with IBS and UC using azocasein as a chromogenic substrate (16, 57, 63) . Most of this activity could be blocked by pan-reactive serine protease inhibitors (16) . Trypsin-like proteases were reported to be increased in patients with IBS and UC by using fluorogenic substrates (6, 35) and in a mouse model of colitis using a p-nitroanilide chromogenic substrate (48) . One key protease that can cleave these substrates is tryptase, a mast cell-derived serine protease known for its roles in anaphylaxis and allergic response (67) . In accordance with increased proteolytic activity, tryptase mRNA and protein were detected at higher levels in IBS and IBD patient biopsies, and this correlated with an increased number of mast cells in these tissues compared with normal colon (37, 42) . Covalent activity-based probes exist for tryptase (54) ; however, they have not yet been applied in the context of gastrointestinal disease. These tools would aid in delineating the exact levels of tryptase activity in diseased tissues compared with healthy controls.
Perhaps the most compelling evidence to suggest a role for mast cell tryptase in IBD is the phenotype of the knockout mouse in colitis models (22) . Mice that lack mast cell tryptase are clearly protected from the symptoms of colitis induced by dextran sodium sulfate (DSS) and trinitrobenzenesulfonate (TNBS), exhibiting less weight loss and less severe histology scores. Many inflammatory markers were reduced in the absence of tryptase, including IL-6, IL-1B, CXCL1/2, and MMP-3/-9/-13. Interestingly, neutrophil infiltration was reduced in tryptase knockout mice, suggesting that tryptase may influence neutrophil recruitment, most likely indirectly through induction of CXCL chemokines.
To investigate the value of tryptase as a drug target, Nafamostat was used to treat rats with TNBS-induced colitis (28) . Nafamostat is a broad-spectrum serine protease inhibitor that potently blocks tryptase activity. Upon administration of the drug by enema, symptoms of colitis were abrogated, including weight loss, colon shortening, and colonic damage (28) . Efficacy of Nafamostat was on par with 5-aminosalicylic acid, a drug that is currently used in the clinic to treat IBD. Furthermore, myeloperoxidase activity and neutrophil chemoattractants such as TNF-␣ and CINC-1 were reduced by Nafamostat treatment, providing additional evidence that that tryptase activity is an important regulator of neutrophil recruitment. Given that Nafamostat is not specific for tryptase (14) , it is possible that these effects were mediated by other serine proteases. Early-phase clinical trials with another tryptase inhibitor, APC-2059, showed improved disease activity indexes in 27 of 56 patients with UC (64); however, this trial was discontinued for unknown reasons.
Neutrophil elastase. Neutrophil elastase is a serine protease that is released from azurophilic granules of neutrophils during inflammation. Elastase-like activity was found to be increased in patients with IBD by using the AAPV-p-nitroanilide substrate (46) and BODIPY-elastin (47), a substrate known to be cleaved by neutrophil elastase; proteinase 3 (PR3); cathepsins G, S, L, and K; and various MMPs (53) . Elastase-like activity was also shown to be increased in mouse models of colitis induced by both DSS and TNBS (46, 48) . Elastase mRNA (59, 65) and protein (16) expression is increased in patients with IBD compared with normal controls; however, this increase was not observed in IBS (63) . Mice that lack one copy of the genes for neutrophil elastase and proteinase-3 show improved damage scores in the DSS colitis model (48) , and mice treated with an elastase inhibitor ONO-5046 showed marginal improvements (65) . As in the case of tryptase, activity-based probes and inhibitors that have the ability to distinguish elastase activity from closely related proteases like PR3 will be essential to dissect the specific function of neutrophil elastase in disease (30) .
Intriguingly, endogenous inhibitors of elastase-like proteases are also dysregulated in IBD. mRNA and protein of serpin B1, an inhibitor of neutrophil elastase, PR3, and cathepsin G, is increased in colonic epithelial cells of patients with active UC and in DSS-induced colitis in mice (65) . Limited in vitro data suggest that it may play a role in protecting colonic epithelial cells from death due to oxidative stress. Elafin, which inhibits elastase and PR3, and secretory leukocyte peptidase inhibitor, an inhibitor of elastase, cathepsin G, trypsin, and chymase, were both shown to be strongly increased at the mRNA level in mucosal biopsies taken from inflamed regions of UC and CD (59) . Conversely, elafin mRNA levels were reported by a different group to be substantially decreased in biopsies from IBD patients and in murine colitis by fluorescent in situ hybridization (47, 48) . Mice with enforced expression of elafin were protected from DSS-and TNBS-induced colitis (48) . Elastase-like and trypsin-like protease activities, colonic damage, and inflammatory markers (MPO, NF-B, IL-6, IL-17a, KC) were restored to levels comparable to healthy mice. In a follow-up study, mice with colitis were treated with elafin-expressing lactic acid bacteria, and similar therapeutic effects were observed (47) . Infiltration of macrophages, neutrophils, and T lymphocytes was attenuated in these mice. Overexpression of elafin in Caco-2 cells led to reduced epithelial permeability (48) . Given that these cells do not express elastase, elafin may also be impacting the activity of other proteases. Elafin has also recently been proposed as a therapy for celiac disease based on its effects in a preclinical mouse model; however, here, it does not appear to impact protease activity and instead may function to block the function of tissue transglutaminase (15) . Nonetheless, these data collectively highlight the importance of the balance between proteases and their inhibitors in inflammation.
Cysteine cathepsins. Cysteine cathepsin proteases are known for their roles in inflammatory diseases like pancreatitis (21, 41, 68) , atherosclerosis (8) , and cancer (12, 17, 69) . These multifunctional enzymes have also recently been implicated in IBD. mRNA for cathepsin B and L are increased in CD33 ϩ macrophages of patients with IBD, and simultaneous inhibition of the two proteases resulted in improved histological scores in mice with DSS-induced colitis (45) . By using a fluorescent activity-based probe, GB123, in the piroxicam/IL-10 Ϫ/Ϫ model of CD, the activities of cathepsin B, S, and L were demonstrated to be increased in macrophages within the mucosa (5). In luminal fluids obtained from inflamed colons induced by both piroxicam and DSS, active cathepsin S was secreted at higher levels than in the normal gut (2, 5) .
Mice with TNBS-induced colitis exhibited an increased visceral motor response to colorectal distension, and this pain response was reduced in mice deficient of cathepsin S (5). When healthy mice were given cathepsin S by enema, they exhibited a similar increase in visceral motor response, which could be blocked by pretreatment with a cathepsin S inhibitor, and increased activation of spinal neurons (5) . Cathepsin S has recently been reported to be a biased agonist of proteaseactivated receptor 2 (PAR 2 ) (70). Mice deficient of PAR 2 displayed decreased pain in response to exogenous cathepsin S (5). Although the effects of cathepsin S are at least partially mediated through PAR signaling, this enzyme likely cleaves additional substrates during inflammation that lead to other functions including antigen presentation, nociception via fractalkine cleavage, and extracellular matrix degradation.
Cysteine cathepsins are also upregulated in macrophages associated with human and murine CRC (3, 29, 33, 60) . A quenched ABP called BMV109 was recently used to image cathepsin activity in colorectal tumors in mice and in biopsies of human tumors (60) . Legumain, another cysteine proteases produced by macrophages during inflammation, has also been linked with CRC (11) . High legumain expression in primary tumors correlates with shortened overall survival and survival free of metastasis (20, 24, 36) . The links between inflammation and cancer are clear (23) , and macrophages are thought to promote malignancy (13, 19, 44, 56) . Blocking the activity of macrophage-derived proteases like cathepsins and legumain may prove to be an important strategy for preventing or treating CRC. Furthermore, CRCs have a high density of mast cells and neutrophils; hence, elastase and tryptase are likely to be critical therapeutic targets as well (26, 43) . The role of proteases in CRC has recently been reviewed by Herszényi and colleagues (25) .
Matriptase. In general, increased protease activity is associated with poor outcomes in gastrointestinal disease. Some proteases, however, are considered to be protective, and their loss is associated with negative consequences. Matriptase is a transmembrane serine protease with essential roles in epithelial barrier function. Patients with IBD exhibit reduced matriptase expression (49) . Mice lacking matriptase die shortly after birth showing signs of dehydration due to a compromised epidermis (38) . Conditional knockout mice survive until just after weaning but suffer from persistent diarrhea, inflammation, edema, disruption of colonic morphology, and a general loss of intestinal barrier function (39) . Remarkably, mice that lack matriptase specifically within the intestinal epithelium develop spontaneous inflammation that mimics human IBD (32) . These mice exhibit a greatly reduced life span and a large percentage developed spontaneous adenocarcinoma of the colon. Furthermore, mice that express hypomorphic levels of matriptase are more susceptible to DSS-induced colitis (49) . Although these mice resemble wild-type mice during the first 7 days of DSS treatment, they are unable to recover epithelial barrier function and most die by day 14. This suggests a role for matriptase in resealing the damaged epithelium and repairing interepithelial tight junctions. Matriptase substrates include uPA and PAR 2 . Mice deficient of these proteins, however, can recover from DSS-induced colitis (49) , suggesting that other substrates are likely to mediate the effects of matriptase on barrier function.
Protease-activated receptors. Much of the attention around proteases in gastrointestinal disease has been focused on their ability to function as agonists of protease-activated receptors, in particular PAR 2 . PAR 2 can be cleaved and activated by a large range of proteases, including trypsin, tryptase, elastase, cathepsin S, and matriptase, to initiate canonical and biased signaling pathways (71) . PAR 2 activation has been associated with an increase in epithelial permeability and pain. Supernatants collected from colonic biopsies of IBS patients were able to stimulate a visceral hypersensitivity to colonic distension when infused into mouse colons (6, 16) . This response could be blocked by serine protease inhibitors and PAR 2 antagonists and was abrogated in PAR 2 -deficient mice. These supernatants also increased colonic permeability and disrupted the integrity of epithelial tight junctions in a PAR 2 -mediated manner (16) . PAR 2 knockout mice were protected from TNBS colitis, exhibiting less weight loss, bowel thickening, MPO activity, and microscopic damage than wild-type controls (27) . Given that the activity of many proteases would need to be inhibited to prevent activation of PAR 2 , small-molecule antagonists of PAR 2 may be more efficacious at preventing the symptoms of IBD. Indeed, a peptide-based PAR 2 antagonist, GB88, prevented mortality in the TNBS colitis model, leading to less shortening of the colon, ulceration, edema, and bowel obstruction (40) . PAR 2 antagonism does not prevent proteolytic cleavage of other substrates that may be important for disease pathology; therefore, the need to develop potent and specific protease inhibitors is still relevant and paramount. CRC, and that the balance of proteases and their inhibitors is critical for maintaining normal gut homeostasis. Many of the tools that have been used to study proteases suffer from a lack of selectivity for individual proteases, and most cross-react with multiple enzymes. To more carefully assess the value of proteases as therapeutic targets, improved chemical tools that can directly assess or inhibit the activity of specific proteases in situ are essential. These tools will aid in identifying the cellular source of proteases, the substrates that they cleave [in combination with sophisticated global profiling strategies (31, 50) ], and, ultimately, their precise contribution to disease. As specific tools become available for more diverse proteases, it is likely that other disease-promoting enzymes will be discovered, leading to new therapeutic avenues.
